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Transformation to secondary myelofibrosis (MF) occurs as part of the natural history of polycythemia vera (PPV-
MF) and essential thrombocythemia (PET-MF). Although primary (PMF) and secondary MF are considered similar
diseases and managed similarly, there are few studies specifically focused on the latter. The aim of this study
was to characterize the mutation landscape, and describe the main clinical correlates and prognostic
implications of mutations, in a series of 359 patients with PPV-MF and PET-MF. Compared with PV and ET, the
JAK2V617F and CALR mutated allele burden was significantly higher in PPV-MF and/or PET-MF, indicating a role
for accumulation of mutated alleles in the process of transformation to MF. However, neither the allele burden
nor the type of driver mutation influenced overall survival (OS), while absence of any driver mutation (triple
negativity) was associated with significant reduction of OS in PET-MF, similar to PMF. Of the five interrogated
subclonal mutations (ASXL1, EZH2, SRSF2, IDH1, and IDH2), that comprise a prognostically detrimental high
molecular risk (HMR) category in PMF, only SRSF2 mutations were associated with reduced survival in PET-MF,
and no additional mutation profile with prognostic relevance was highlighted. Overall, these data indicate that
the molecular landscape of secondary forms of MF is different from PMF, suggesting that unknown mutational
events might contribute to the progression from chronic phase disease to myelofibrosis. These findings also
support more extended genotyping approaches aimed at identifying novel molecular abnormalities with
prognostic relevance for patients with PPV-MF and PET-MF.
Am. J. Hematol. 91:681–686, 2016.VC 2016 Wiley Periodicals, Inc.
 Introduction
The chronic myeloproliferative neoplasms (MPN) polycythemia vera (PV) and essential thrombocythemia (ET) can evolve to secondary forms of mye-
lofibrosis, known as postpolycythemia vera (PPV-MF) and postessential thrombocythemia (PET-MF) myelofibrosis, as part of their natural history [1].
Reported rates of transformation are 10–15 and 5–10%, respectively for PV and ET, at 15 years from initial diagnosis, but these figures may be inaccurate
due to the retrospective nature of studies, small series reported, variability of diagnostic criteria [2]. More recently, strict criteria for diagnosing transforma-
tion to PPV-MF and PET-MF have been delineated by the International Working Group for Myeloproliferative neoplasms Research and Treatment
(IWG-MRT), that should result in more homogeneous patient series and facilitate controlled studies [3]. Histopathologic findings and clinical manifesta-
tions are very similar in secondary MF and the primary form of disease (primary myelofibrosis, PMF), and also the pathophysiological mechanisms leading
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to deposition of fibers and other typical abnormalities of bone marrow
microenvironment, including neoangiogenesis and osteosclerosis, are
considered to be akin.
Few studies have specifically focused on secondary forms of
myelofibrosis, and it is common practice to manage them in the
same way as PMF. While this is likely appropriate in terms of
therapeutic management, as supported also by the comparable effi-
cacy of JAK2 inhibitors in subgroup analysis of patients treated
with ruxolitinib [4,5] fedratinib [6], and pacritinib [7], it remains
to be fully addressed whether the clinical course of secondary MF
differs from PMF and which are the variables eventually influenc-
ing it. In particular as regards prognosis, there are evidences that
the International Prognostic Score System (IPSS), that is routinely
employed for both PMF and secondary MF, may not be perform-
ing satisfactorily in secondary forms of MF [8]. Even less is known
about the relevance of the mutational background in secondary
MF. It has been shown that certain somatic mutations exhibit
strong prognostic relevance in PMF when considered either indi-
vidually [9–11] or in combination [12,13]. Patients with PMF who
have the CALR type 1/type 1-like mutation constitute a group
with a more favorable disease compared with those who are CALR
type 2/type 2-like, JAK2V617F or MPLW515x mutated [14–16],
and patients who result negative for the 3 driver mutations men-
tioned above (so called “triple negative” patients) are at even
greater risk of earlier death [11]. Furthermore, a category of “High
Molecular Risk” (HMR) patients was defined to include those
patients who harbor any mutation in ASXL1, EZH2, SRSF2, IDH1,
and IDH2; HMR patients have significantly shorter overall survival
and enhanced risk of transformation to acute leukemia [12,17]
compared with those who lack prognostically detrimental muta-
tions. In addition, the number of HMR mutations, and widely the
number of subclonal mutations, represents a strong negative pre-
dictor of survival for patients with PMF [18,19].
The aim of current study was to describe the mutation landscape
and analyze the clinical impact of mutation profile, considering both
driver and selected subclonal mutations, in a well characterized multi-
center cohort of patients with PPV-MF and PET-MF.
 Methods
Patients. We retrospectively collected clinical and hematologic information of
359 patients with secondary MF; diagnosis of PPV-MF and PET-MF was according
to the IWG-MRT criteria [3]. Patients were collected from 5 tertiary centers (Flor-
ence, Pavia, Bergamo, Torino and Varese) belonging to the Italian cooperative
group AGIMM (AIRC- Gruppo Italiano Malattie Mieloproliferative). The study was
performed in accordance with the Declaration of Helsinki and an informed consent
was obtained; the research protocol was approved by the local Ethical committees.
Clinical parameters evaluated were: leukocyte count, hemoglobin and platelet levels,
peripheral blast count, presence of constitutional symptoms, palpable splenomegaly
(measured as cm from the left costal margin, LCM), and patient age at diagnosis of
PPV-MF and PET-MF. Specific karyotypic abnormalities and cytogenetic risk cate-
gories were defined as described for patients with PMF [20].
Mutation analysis. A peripheral blood sample was collected at the time of diag-
nosis; granulocytes were isolated by density gradient centrifugation and processed for
DNA purification. JAK2V617F and MPLW515x mutations were detected by real-time
quantitative PCR; for MPL mutations, also high-resolution melting analysis followed
by bidirectional Sanger sequencing was employed [21]. Calreticulin (CALR) muta-
tions were identified by capillary electrophoresis followed by bidirectional sequencing
in case of abnormal traces, and classified as type 1/type 1-like or type 2/type 2 like,
as reported [16,22]. Patients lacking mutations in driver genes, JAK2, MPL and
CALR, were operationally defined as “triple negative” (TN) [11,21]. A Next Genera-
tion Sequencing (NGS) technique based on the PGM Ion Torrent platform was used
to detect mutations across the entire coding region of ASXL1, and EZH2, and regions
previously described as mutational hotspots for IDH1, IDH2, and SRSF2. A high
molecular risk status (HMR) was defined by the presence of 1 mutated gene, as
described for patients with PMF [12]. In case of mutations not previously reported
in public databases, only those considered as potentially damaging by Polyphen
algorithm (http://genetics.bwh.harvard.edu/pph2/) were included for analysis.
Statistical analyses. Follow-up was measured as the interval from the diagnosis
of PPV-MF and PET-MF to death or last follow-up date; patients who received
stem cell transplant were censored on the date of transplant procedure. The cumu-
lative probability of overall survival (OS) and leukemia free-survival (LFS) were
estimated using the Kaplan–Meier method. Differences in OS among the groups
were compared by using a log-rank test in univariate analysis. All P< 0.05 were
considered as statistically significance. Statistical analyses were performed using the
IBM Statistical Package for Social Sciences (SPSS) statistics v23.
 Results
This study included 359 patients with secondary MF, of which 194
had PPV-MF and 165 PET; their clinical characteristics are reported in
Table I. Median age was 64 and 63 years, respectively, the proportion
TABLE I. Patients’ Characteristics
Variables PPV (n5 194) PET (n5 165) P
Males [n (%)] 101 (52.1%) 90 (54.5%) 0.358
Age in years; median (range) 64.4 (34–91) 63.2 (27–94) 0.238
Hemoglobin (g/L); median (range) 128 (74–18.0) 109 (50–156) <0.0001
Hemoglobin <100 g/L, n (%) 30 (15.5%) 58 (35.1%) <0.0001
Leucocytes 3109/L; median (range) 12.3 (1.7–98.4) 7.8 (1.1–48.0) <0.0001
Leucocytes >25 3 109/L; n (%) 32 (16.5%) 10 (6.1%) 0.002
Leucocytes >30 3 109/L; n (%) 22 (11.3%) 5 (3.0%) 0.002
Platelets, 3109/L; median (range) 294 (16–1689) 375 (19–1213) 0.017
Platelets <100 3 109/L; n (%) 20 (10.2%) 13 (7.9%) 0.273
Circulating blasts 1%; n (%) 54 (27.8%) 49 (29.7%) 0.367
Constitutional symptoms; n (%) 94 (48.4%) 59 (35.7%) 0.014
Splenomegaly; n (%)















High 7 (6.9%) 2 (2.4%) 0.138
Intermediate 2 4 (13.9%) 9 (11.0%)
Intermediate 1 13 (12.9%) 5 (6.1%)
Progression to leukemia; n (%) 16 (8.2%) 19 (11.5%) 0.194
Death; n (%) 67 (34.5%) 49 (29.7%) 0.194
a LCM: left costal margin.
b Unfavorable karyotype: high, monosomal karyotype, inv(3), i(17q), 27/7q2, 11q or 12p abnormality; intermediate2: complex nonmonosomal, two abnormalities not
included in very high risk category, 5q2, 18, other autosomal trisomies except 19, and other sole abnormalities not included in other risk categories; Intermediate1:
sole abnormalities of 20q2, 1q1 or any other sole translocation, and -Y or other sex chromosome abnormality; low: normal or sole abnormalities of 13q2 or 19.
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of male patients was similar (52 and 54%). Patients with PPV-MF had
higher hemoglobin levels and leukocyte count (P< 0.0001 for both)
than those with PET-MF, while platelet counts were higher in PET-MF
(P5 0.017). There were more anemic patients (Hb< 100 g/L) among
PET-MF than PPV-MF (35.1 versus 15.5%; P< 0.0001); conversely,
more patients with PPV-MF suffered from constitutional symptoms
(48.4% versus 35.7% of PET-MF; P5 0.014) and had palpable spleno-
megaly (92.3 versus 82.4%; P5 0.004) and larger splenomegaly (43.3
versus 21.2%; P< 0.0001) than PET-MF. Information about karyotype
at the time of myelofibrosis transformation was available in 52.1 and
49.7% of PPV-MF and PET-MF; there were more abnormal karyotypes
among PPV-MF than PET-MF patients (42.6 and 24.4%, respectively;
P5 0.007), while karyotype risk classes were similarly represented in
the two groups (Table I).
The patients’ mutation profile is reported in Table II. All PPV-MF
patients harbored the JAK2V617F mutation compared with 49.1% of
PET-MF; 9.7% and 33.9% of PET-MF were MPLW515x and CALR
mutated, respectively. The mean (6SD) allele burden of JAK2V617F
mutation was higher in PPV-MF (75.76 20.3%) than PET-MF
(56.26 24.9%; P< 0.0001); furthermore, the JAK2V617F allele burden
was significantly higher in PPV-MF and PET-MF than in a population of
369 JAK2V617F mutated patients with PV (44.56 22.2; P< 0.0001) and
402 with ET (26.56 13.6%; P< 0.0001), randomly selected from our
archives. We also compared the percentage of patients with PPV-MF and
PV who had more than 50 and 75% mutated alleles: the figures were
88.7% and 55.3% for PPV-MF compared with 34.0 and 10.6% for PV
(P< 0.0001 for both). Similarly, significantly more patients with PET-MF
had JAK2V6171F allele burden greater than 25% (91.7%) or 50% (49.1%)
than those with ET (56.5 and 7.4%, respectively; P< 0.0001 for both).
In PET-MF, CALR type1/type1-like mutations were more repre-
sented than type2/type2-like (71.4 versus 28.6%; P< 0.0001), while
the allele burden was similar for the two mutation types (55.86 7.5%
and 51.76 23.7%, respectively; P5 0.287). The overall CALR mutated
allele burden was higher in PET-MF than in ET patients (54.86 13.6
versus 44.76 10.7; P< 0.0001); specifically, it was 55.8% versus 46.3%
for CALR type1/type1-like (P5 0.0004) and 51.7% versus 43.0% for
CALR type2/type2-like mutations (P5 0.049), respectively in patients
with PET-MF and ET. There were significantly more patients with a
CALR allele burden greater than 50% in PET-MF than in ET (51.0
versus 20.4%; P< 0.0001).
A total of 48 PPV-MF patients (24.7%) and 59 PET-MF (35.8%)
harbored at least one mutation in ASXL1, EZH2, SRSF2, IDH1 and
IDH2, and were thereby considered as HMR patients (Table II); the
difference between PET-MF and PPV-MF was statistically significant
(P5 0.028). In particular, more PET-MF patients were ASXL1 and
EZH2 mutated compared with PPV-MF [29.1 versus 17.0%
(P5 0.011) and 10.3 versus 3.6% (P5 0.022), respectively]. Six
patients in each group had 2 or more mutated genes (3.1 and 3.6%
for PPV-MF and PET-MF). When compared with a cohort of 483
PMF patients from our data base, there were more EZH2 mutations
in PET-MF than in PMF (10.3 versus 5.1%; P5 0.03) while con-
versely the percentage of patients with 2 mutations was significantly
lower than in PMF (8.0%; P5 0.003).
With an overall median follow-up period of 3.9 years (3.9 years
for PPV-MF and 3.8 years for PET-MF) 116 deaths were recorded in
the whole series (32.3%), accounting for 34.5 and 29.7% of PPV-MF
and PET-MF. Sixteen PPV-MF (8.2%) and 19 PET-MF (11.5%)
patients transformed to acute leukemia. The median OS was 7.4 years
(HR 1.2, 95% CI 0.8–2.7) for PPV-MF and 14.5 years for PET-MF,
not statistically different (P5 0.339) [Fig. 1(A)]; median LFS was not
reached in either groups [Fig. 1(B)]. The median time of transforma-
tion to PPV-MF and PET-MF was 10.1 years (range 1.1–30.7) and
11.5 years (0.9–3.6), respectively (P5 0.101). A longer (>10 years)
duration of the chronic PV phase was associated with shorter OS
TABLE II. Mutation Profile for Driver and High Molecular Risk (HMR) Mutationsa
in Patients with PPV-MF and PET-MF
PPV (n5 194) PET (n5 165) P
JAK2V617F; n (%) 194 (100%) 81 (49.1%) <0.0001
V617F allele burden (%);
mean6SD
75.7620.3 56.26 24.9 <0.0001
MPLW515; n (%) – 16 (9.7%) –
CALR mutated; n (%) – 56 (33.9%) –




55.86 7.5/51.76 23.7 0.287
Triple negative; n (%) – 12 (7.3%) –
ASXL1 mutated; n (%) 33 (17.0%) 48 (29.1%) 0.011
EZH2 mutated; n (%) 7 (3.6%) 17 (10.3%) 0.022
IDH1/2 mutated; n (%) 11 (5.7%) 2 (1.2%) 0.055
SRSF2 mutated; n (%) 2 (1.0%) 7 (4.2%) 0.096
HMR patients; n (%) 48 (24.7%) 59 (35.7%) 0.028
N. HMR mutations 2;
n (%)
6 (3.1%) 6 (3.6%) 0.960
a Genes included in the HMR category are ASXL1, EZH2, SRSF2, IDH1, IDH2 [12].
b Type 1 and type 2 includes type 1-like and type 2-like mutations according
to the criteria in [22].
Figure 1. Overall survival (OS) and leukemia free-survival (LFS) of patients
with PPV-MF and PET-MF are presented in panel A and B, respectively. In
case of OS, the hazard ratio (HR, 95% CI) was calculated using PET-MF as
the reference group while in case of LFS PPV-MF was used as the refer-
ence group.
RESEARCH ARTICLE Mutation Profile in Secondary Myelofibrosis
doi:10.1002/ajh.24377 American Journal of Hematology, Vol. 91, No. 7, July 2016 683
once transformed to PPV-MF (HR 2.26; 95% CI, 5.87–6.45; P5
0.004), while no such difference was seen for ET. Conversely, longer
(>10 years) duration of chronic ET phase was associated with signifi-
cantly shortened LFS after transformation to PET-MF (HR 4.42, 95%
CI 1.01–20.06; P5 0.036). After stratifying patients according to the
IPSS risk criteria, we found that 52.6% of PPV-MF and 47.3% of
PET-MF were comprised in the higher risk categories (Supporting
Information Table I); however, only the high risk category resulted
clearly separated from the others, confirming the poor performance
of IPSS in secondary MF (Supporting Information Fig. 1).
We first compared hematological and clinical characteristics of
PET-MF patients who were categorized according to their driver
mutation status (Supporting Information Table II). We found no sig-
nificant differences among mutational groups regarding age, hemoglo-
bin, leucocyte, and platelet count, peripheral circulating blast cells
and abnormal karyotype. However, significantly more JAK2V617F
positive patients referred constitutional symptoms (P5 0.003), espe-
cially in comparison with CALR mutated patients (P< 0.0001); also,
large splenomegaly was found in 29.6% of JAK2V617F mutated com-
pared with 12.5% of CALR mutated patients (P< 0.001). Higher IPSS
risk category were more frequent among JAK2V617F mutated
patients (59.3%) compared with the other groups (33.9% CALR,
37.5% MPL. 41.6% in TN patients). Information about thrombosis
were available in 68 patients; those harboring JAK2V617F mutation
displayed more thrombotic events than CALR mutated (43.3% versus
22.2% in CALR type1 and no case in CALR type2; P5 0.023). The
interval from ET phase to myelofibrosis progression was significantly
longer in CALR type2 (18.9 years) compared with type1 (12.2 years),
JAK2V617F (10.6 years), MPL (14.4 years) and particularly TN (8.1
years) (P5 0.015). Finally, CALR type1 mutated patients had reduced
rate of death in comparison with CALR type2, JAK2 and TN (17.5
versus 25.0%, 32.1 and 75%, respectively; P5 0.003). ASXL1 muta-
tions were particularly associated with CALR type2, MPLW515x and
TN (P5 0.013), while six of seven SRSF2 mutation were associated
with JAK2V617F mutation (Supporting Information Table II). No
other meaningful correlation could be outlined.
We then evaluated the impact of driver and subclonal mutations for
prognosis. Since all PPV-MF patients were JAK2V617F mutated, we
divided patients according to quartiles of allele burden, but did not find
any significant correlation with either OS (Table III) or LFS (not shown
in detail). In case of PET-MF, we considered 5 mutational groups, rep-
resented by CALR (type1/type1-like and type2/type2-like), JAK2V617F,
MPLW515x and TN patients [Table IV and Supporting Information
Fig. 2(A)]. Since there was no difference between CALR type1 and type2
(P5 0.29), we used the former as reference group. We found that only
triple negativity was associated with shorter survival (HR 3.71, 95% CI
1.36–10.06; P5 0.010) while other genotypes were irrelevant. No impact
on LFS could be demonstrated. We also did not find difference in OS
between PPV-MF and PET-MF patients who were JAK2V617F mutated
[Supporting Information Fig. 2(B)]. Analysis of the impact of HMR
mutations in PPV-MF failed to discover correlations of either single
gene mutations, a HMR status or the number of HMR mutations with
OS [Table III and Supporting Information Fig. 2(C)] and LFS (not
shown). As regards PET-MF, a HMR status was not predictive of
reduced OS [Supporting Information Fig. 2(D)], while we found a
significant correlation of SRSF2 mutations with shortened survival
(HR 4.90, 95%CI 1.70–14.12; P5 0.001) [Table IV and Supporting
Information Fig. 2(E)]; median survival was 14.5 years in SRSF2 wild
type compared with 4.9 years in SRSF2 mutated patients. No impact on
LFS could be demonstrated (not shown).
TABLE III. Analysis of the Impact of the JAK2V617F Allele Burden and High Molecular Risk (HMR) Mutationsb on Survival of Patients with PPV-MF
Variable N (%)b Median OS (range) (years) HRa,c 95% CI P value
JAK2V617F allele burden quartile
1–50% 24 (12.0) NR – – –
51–75% 66 (34.0) 7.18 (5.82–8.55) 3.13 0.74–13.32 0.122
76–100% 104 (54.0) 8.43 (5.06–11.80) 2.27 0.54–9.58 0.265
ASXL1 mutations 33 (17.0%) 6.12 (4.83–7.41) 1.48 0.80–2.77 0.208
EZH2 mutations 7 (3.6%) NR 1.18 0.29–4.84 0.821
IDH1/2 mutations 11 (5.7%) NR 1.64 0.50–5.33 0.407
SRSF2 mutations 2 (1.0%) NR 1.24 0.17–9.00 0.832
HMR status 48 (24.7%) 6.12 (4.73–7.51) 1.64 0.93–2.89 0.084
N. HMR mutations2 6 (3.1%) NR 1.75 0.42–7.31 0.442
a The reference group for JAK2V617F mutated patients was quartile 1 (1–25%).
b Genes included in the HMR category are ASXL1, EZH2, SRSF2, IDH1, IDH2 [12].
c The reference group was patients without HMR mutations (n5 146).
TABLE IV. Analysis of the Impact of Driver and High Molecular Risk (HMR) Mutationsa on Survival of Patients with PET-MF
Variable N (%)a Median OS (range) (years) HRb,c 95% CI P value
CALR type1a 40 (24.3) NR – – –
CALR type2a 16 (9.7) NR 1.88 0.55–6.43 0.314
JAK2V617F—PET 81 (49.1) 10.9 (6.12–15.76) 2.08 0.90–4.80 0.080
MPLW515 16 (9.7) NR 1.09 0.28–4.23 0.898
Triple negative 12 (7.3) 4.81 (2.27–7.35) 3.71 1.36–10.06 0.010
ASXL1 mutations 48 (29.1%) 14.50 (7.20–20.99) 1.37 0.74–2.55 0.314
EZH2 mutations 17 (10.3%) NR 0.79 0.28–2.23 0.660
IDH1/2 mutations 2 (1.2%) NR 0.33 0.01–101.86 0.192
SRSF2 mutations 7 (4.2%) 3.04 (2.38–3.70) 4.90 1.70–14.12 0.001
HMR status 59 (35.7%) 6.41 (2.50–10.88) 1.47 0.80–2.68 0.211
N. HMR mutations 2 6 (3.6%) 4.72 (2.11–7.34) 1.97 0.60–6.56 0.379
a Genes included in the HMR category are ASXL1, EZH2, SRSF2, IDH1, IDH2 [12].
b The reference group for driver mutations (JAK2V617F, MPLW515x, CALR, and for triple negativity) was CALR type1/type1-like.
c The reference group was patients without HMR mutations (n5 106).
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 Discussion
Results from this study describe for the first time the mutation
landscape, and the main clinical correlates and prognostic implica-
tions of mutations, in a large series of well-characterized patients
with PPV-MF and PET-MF. Current information about characteris-
tics, disease course and prognosis in secondary myelofibrosis are
quite scanty, largely due to the lack of enough powered study to
address these points. Similarly, the knowledge about the molecular
profile of the patients, which conversely has been well characterized
in PMF patients, is poor. This also reflects the current practice of
managing PMF and secondary forms of myelofibrosis as the same
in terms of therapeutic approaches and prognosis stratification,
although, for example, there is evidence that the IPSS score is not
satisfactorily performing in this setting of patients as in those with
PMF [8], for which it was specifically devised [23]. Not to mention,
furthermore, that in clinical trials with newest JAK2 inhibitors or
other targeted molecules, the entry criteria have been the same for
the two categories of patients [24,25]; reassuringly, there was no evi-
dence of differences in terms of hematological and/or clinical
responses between PMF and secondary MF, but a potential bias
when considering the impact of drugs on survival has not been
clearly ruled out, although a PPV-MF and PET-MF subtype were
associated with better outcome in general [26]. Therefore, it is
important to specifically focus on PPV-MF and PET-MF as distinct
entities to develop better performing tools to interpret disease char-
acteristics and clinical.
There is circumstantial evidence that driver mutation profile of
patients with PMF is associated with clinical characteristics of the
patients and identifies different prognostic groups. Apart from PV
patients, who were all JAK2V617F mutated as expected, the propor-
tion of PET-MF patients with JAK2V617F and CALR mutations in
this series was comparable to reports in PMF and ET; however, nota-
bly, CALR type1 mutation was harbored by 71% of CALR mutated
patients compared with 29% of type2, contrasting with the roughly
balanced representation of the two mutations types in ET, thereby
reinforcing previous suggestions regarding a role for CALR type1 in
myelofibrotic transformation [11,27,28]. Accordingly, we also found
that the myelofibrosis-free survival was longer in CALR type2 patients
than all other genotypes. Interestingly, in retroviral model of CALR
mutation, mice expressing type1 mutations developed more severe
myelofibrosis trait as compared with type2 [29]. On the opposite, an
excess of CALR type2 mutations was found in Chinese patients with
PMF (64% versus 32% type1) [30] suggesting possible genetic back-
ground differences. Also, we found herein that the frequency of MPL
mutated patients in PET-MF (9.7%) was higher than reported in ET
(2 to 4%) [21,31,32]. In a previous study [21], we found that MPL
mutated ET patients had greater likelihood of transforming to PET-
MF compared to other genotypes, but due to small number of events
such difference did not reach the significance level; more recently,
Elala et al reported shorter myelofibrosis-free survival in MPL
mutated ET patients that remained significant in multivariate analy-
sis, thereby corroborating our current findings [33]. On the other
hand, results of this study validate and extend previous observations
concerning the role of accumulation of mutated alleles of JAK2V617F
[34–36] in the progression to PPV-MF and PET-MF, although we
show here that allele burden did not impact on overall survival. We
also report that CALR allele burden of PET-MF patients was signifi-
cantly higher compared with a series of ET patients from our
archives, indicating that a CALR allele burden greater than 50% is far
more frequent in PET-MF than ET. The retrospective comparative
nature of these observations imposes caution, and prospective follow-
up analysis of individual cases might help to define the role of accu-
mulating CALR alleles in the progression to PET-MF.
Concerning the prognostic impact of driver mutations, data in
PMF patients indicated that the CALR type1/type1 like mutations
identified patients with longer survival as compared to JAK2V617F,
MPLW515x and CALR type2/type2 mutated [14,16,22]; in most stud-
ies, the triple negative patients experienced the shorter survival
[11,16]. However, the survival advantage of CALR type1/type1-like
versus type2/type2-like in PMF has generated some conflicting data
[27,28]. In this series of PET-MF, we found that survival was largely
superimposable among the varying mutational groups, with the nota-
ble exception of triple negative patients who did worse, as in PMF.
Here, we did not find differences between CALR type1/type1-like and
type2/type2-like. Therefore, in secondary MF, driver mutations do
not appear to meaningfully predict survival, at variance with PMF.
Mutations in selected subclonal genes have been shown to be prog-
nostically predictive in PMF [9,12,13,37,38]; a HMR category was
devised to include patients with at least one mutation in ASXL1, EZH2,
SRSF2, IDH1, and IDH2 who suffered from shortened overall survival
and more frequent transformation to leukemia. In the current series of
secondary MF, we found that, although the frequency of these mutated
genes was roughly comparable to PMF, they did not inform prognosis
nor leukemia transformation, with the notable exception of SRSF2
mutations in PET-MF that predicted for shorter survival. As reported in
PMF, we also found that mutations in the spliceosome gene SRSF2 are
mainly associated with JAK2V617F mutated or triple negative patients
and are infrequently combined with CALRmutations (no patient in this
series out of 7 mutated) [15]. The percentage of patients with 2 or more
HMR mutations was too low to evaluate an impact of mutation number
on prognosis, as it was reported in PMF [18].
In summary, we conclude that, at variance with PMF, the mutation pro-
file of secondary forms of myelofibrosis does not remarkably inform prog-
nostic assessment, leaving open many questions regarding the texture of
genetic changes that promote evolution from chronic phase disease to mye-
lofibrosis and are responsible for the shortened survival associated with
such transformation. For the clinical practice, these data also indicate that
using current molecular target analysis for prognostication, including the
HMR category, should be reserved to patients with PMF only.
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